Autism Spectrum Disorders Market By Disease (Autistic Disorder, Asperger Syndrome, Pervasive development disorder, Other), By Service, By Location : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global autism spectrum disorder treatment market was valued at $27,272.7 million in 2021, and is projected to reach $43,166.16 million by 2031, registering a CAGR of 4.6% from 2022 to 2031.

A class of sophisticated neurological illnesses known as autism spectrum disorder (ASD) is characterized by a wide range of behavioral patterns and difficulties with social interaction and communication. Compulsive behavior, incorrect social interaction, a learning handicap, anxiety, sensitivity to hearing, repetitive motions, and many other characteristics are among the key indications and symptoms of ASD.

The increase in prevalence of autism spectrum disorder and rise in demand for early diagnosis of autism spectrum disorders boost the growth of market. For instance, in November 2021, as per the study of Ben-Gurion University researchers and colleagues, it was found that, autism spectrum disorder diagnosis by 2.5 years of age leads to dramatic improvements in social symptoms as compared to those diagnosed later in life. Thus, rise in awareness about autism spectrum disorder and rise in demand for early diagnosis of autism spectrum disorder drive the growth of market.

Moreover, the increase in prevalence of autism spectrum disorder and rise in awareness regarding service of autism spectrum disorder are the key factors that drive the growth of autism spectrum disorder treatment market. For instance, in March 2022, as per the report of World Health Organization (WHO), it was estimated that worldwide about one in 100 children has autism spectrum disorder.

Furthermore, the increase in awareness about autism spectrum disorder and rise in contribution of government & non-government organizations to provide autism spectrum disorder diagnosis & service propel the growth of market. For instance, ASERT (Autism Services, Education, Resources and Training) is an organization of medical centers, and universities, announced the launch of Autism Awareness, Community Education and Support (AACES), a program designed to increase independence and decrease isolation among young people with autism spectrum disorder (ASD).

Moreover, the increase in R&D activities for development of advanced autism spectrum disorder treatment, advancements in diagnosis of disease, rise in U.S. food and drug administration (USFDA) approvals, and novel product launch in market by key players boost the market growth. For instance, in October 2021, Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and diseases, received clearance from the U.S. Food and Drug Administration (FDA) of its investigational new drug (IND) application for lead candidate, AB-2004, a gut-targeted, molecular therapeutic for the service of irritability associated with autism spectrum disorder. Furthermore, advancements in autism spectrum disorder treatments such as online training platforms and mobile diseases for autism spectrum further contribute in market growth. However, the high cost of autism spectrum disorder treatment and lack of awareness about disease may hinder the growth of market.

The Autism spectrum disorder treatment market is segmented on the basis of service, disease, location and region. By service , the market is classified into behavioral approaches, early intervention, medication, and others.

Depending on disease, the market is classified into autistic disorder, asperger's syndrome, and pervasive development disorder (PDD).

By location, market is categorized into hospital, education counsellor center, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include: Abbvie Inc, Axial therapeutics, The Bristol Myers Squibb Company, Cognoa Inc, Curemark LLC, Dfusion Inc, EarliTec Diagnostics Inc, Jaguar Gene Therapy, Jazz Pharmaceuticals, Johnson & Johnson, Neurim Pharmaceuticals Ltd., Novartis AG, PaxMedica Inc, Pfizer Inc, Stalicla SA, Teva Pharmaceutical Industries Ltd. and Yamo Pharmaceuticals LLC.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the autism spectrum disorders market analysis from 2021 to 2031 to identify the prevailing autism spectrum disorders market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the autism spectrum disorders market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global autism spectrum disorders market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease

Autistic Disorder
Asperger Syndrome
Pervasive development disorder (PDD)
Other

By Service

Behavioural Approaches
- Gender
- Male
- Female
Early Intervention
- Gender
- Male
- Female
Medication
- Gender
- Male
- Female
Other Services
- Gender
- Male
- Female

By Location

Hospitals
Education Counsellor Center
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbvie Inc
- Axial therapeutics
- Bristol Myers Squibb Co.
- Cognoa Inc
- Curemark LLC
- dfusion inc.
- EarliTec Diagnostics Inc
- Jazz Pharmaceuticals
- Johnson & Johnson
- Novartis AG

Product Code: A13338

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Autistic Disorder
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Asperger Syndrome
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Pervasive development disorder (PDD)
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
4.5 Other
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country

CHAPTER 5: AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Behavioural Approaches
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.2.4 Behavioural Approaches Autism Spectrum Disorders Market by Gender
  - 5.2.4.1 Male Market size and forecast, by region
  - 5.2.4.2 Female Market size and forecast, by region
5.3 Early Intervention
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.3.4 Early Intervention Autism Spectrum Disorders Market by Gender
  - 5.3.4.1 Male Market size and forecast, by region
  - 5.3.4.2 Female Market size and forecast, by region
5.4 Medication
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.4.4 Medication Autism Spectrum Disorders Market by Gender
  - 5.4.4.1 Male Market size and forecast, by region
  - 5.4.4.2 Female Market size and forecast, by region
5.5 Other Services
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.5.4 Other Services Autism Spectrum Disorders Market by Gender
  - 5.5.4.1 Male Market size and forecast, by region
  - 5.5.4.2 Female Market size and forecast, by region

CHAPTER 6: AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospitals
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Education Counsellor Center
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Others
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: AUTISM SPECTRUM DISORDERS MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Disease
- 7.2.3 North America Market size and forecast, by Service
  - 7.2.3.1 North America Behavioural Approaches Autism Spectrum Disorders Market by Gender
  - 7.2.3.2 North America Early Intervention Autism Spectrum Disorders Market by Gender
  - 7.2.3.3 North America Medication Autism Spectrum Disorders Market by Gender
  - 7.2.3.4 North America Other Services Autism Spectrum Disorders Market by Gender
- 7.2.4 North America Market size and forecast, by Location
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Disease
  - 7.2.5.1.2 Market size and forecast, by Service
  - 7.2.5.1.3 Market size and forecast, by Location
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Disease
  - 7.2.5.2.2 Market size and forecast, by Service
  - 7.2.5.2.3 Market size and forecast, by Location
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Disease
  - 7.2.5.3.2 Market size and forecast, by Service
  - 7.2.5.3.3 Market size and forecast, by Location
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Disease
- 7.3.3 Europe Market size and forecast, by Service
  - 7.3.3.1 Europe Behavioural Approaches Autism Spectrum Disorders Market by Gender
  - 7.3.3.2 Europe Early Intervention Autism Spectrum Disorders Market by Gender
  - 7.3.3.3 Europe Medication Autism Spectrum Disorders Market by Gender
  - 7.3.3.4 Europe Other Services Autism Spectrum Disorders Market by Gender
- 7.3.4 Europe Market size and forecast, by Location
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Disease
  - 7.3.5.1.2 Market size and forecast, by Service
  - 7.3.5.1.3 Market size and forecast, by Location
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Disease
  - 7.3.5.2.2 Market size and forecast, by Service
  - 7.3.5.2.3 Market size and forecast, by Location
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Disease
  - 7.3.5.3.2 Market size and forecast, by Service
  - 7.3.5.3.3 Market size and forecast, by Location
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Disease
  - 7.3.5.4.2 Market size and forecast, by Service
  - 7.3.5.4.3 Market size and forecast, by Location
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Disease
  - 7.3.5.5.2 Market size and forecast, by Service
  - 7.3.5.5.3 Market size and forecast, by Location
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Disease
  - 7.3.5.6.2 Market size and forecast, by Service
  - 7.3.5.6.3 Market size and forecast, by Location
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Disease
- 7.4.3 Asia-Pacific Market size and forecast, by Service
  - 7.4.3.1 Asia-Pacific Behavioural Approaches Autism Spectrum Disorders Market by Gender
  - 7.4.3.2 Asia-Pacific Early Intervention Autism Spectrum Disorders Market by Gender
  - 7.4.3.3 Asia-Pacific Medication Autism Spectrum Disorders Market by Gender
  - 7.4.3.4 Asia-Pacific Other Services Autism Spectrum Disorders Market by Gender
- 7.4.4 Asia-Pacific Market size and forecast, by Location
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Disease
  - 7.4.5.1.2 Market size and forecast, by Service
  - 7.4.5.1.3 Market size and forecast, by Location
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Disease
  - 7.4.5.2.2 Market size and forecast, by Service
  - 7.4.5.2.3 Market size and forecast, by Location
  - 7.4.5.3 Australia
  - 7.4.5.3.1 Market size and forecast, by Disease
  - 7.4.5.3.2 Market size and forecast, by Service
  - 7.4.5.3.3 Market size and forecast, by Location
  - 7.4.5.4 India
  - 7.4.5.4.1 Market size and forecast, by Disease
  - 7.4.5.4.2 Market size and forecast, by Service
  - 7.4.5.4.3 Market size and forecast, by Location
  - 7.4.5.5 Rest of Asia-Pacific
  - 7.4.5.5.1 Market size and forecast, by Disease
  - 7.4.5.5.2 Market size and forecast, by Service
  - 7.4.5.5.3 Market size and forecast, by Location
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Disease
- 7.5.3 LAMEA Market size and forecast, by Service
  - 7.5.3.1 LAMEA Behavioural Approaches Autism Spectrum Disorders Market by Gender
  - 7.5.3.2 LAMEA Early Intervention Autism Spectrum Disorders Market by Gender
  - 7.5.3.3 LAMEA Medication Autism Spectrum Disorders Market by Gender
  - 7.5.3.4 LAMEA Other Services Autism Spectrum Disorders Market by Gender
- 7.5.4 LAMEA Market size and forecast, by Location
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Disease
  - 7.5.5.1.2 Market size and forecast, by Service
  - 7.5.5.1.3 Market size and forecast, by Location
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Disease
  - 7.5.5.2.2 Market size and forecast, by Service
  - 7.5.5.2.3 Market size and forecast, by Location
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Disease
  - 7.5.5.3.2 Market size and forecast, by Service
  - 7.5.5.3.3 Market size and forecast, by Location
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Disease
  - 7.5.5.4.2 Market size and forecast, by Service
  - 7.5.5.4.3 Market size and forecast, by Location

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Abbvie Inc
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Axial therapeutics
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Bristol Myers Squibb Co.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Cognoa Inc
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Curemark LLC
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 dfusion inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 EarliTec Diagnostics Inc
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Jazz Pharmaceuticals
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Johnson & Johnson
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Novartis AG
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments